The Life Sciences Report

*

Merck & Co. Inc. TICKER: MRK:NYSE Merck & Co Inc. is a global healthcare leader working to help the world be well. Known as as MSD outside the United States and Canada, the company works with customers and operates in more than 140 countries to deliver innovative health solutions through prescription medicines, vaccines, biologic therapies and consumer care and animal health products. Merck also demonstrates its commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.

Expert Comments:

ValuEngine (4/5/13) "We have issued a Buy recommendation for Merck & Co. Inc. on April 5, 2013. Based on the information we have gathered and our resulting research, we feel that the company has the probability to outperform average market performance for the next year; Merck exhibits attractive company size, volatility and price-to-earnings ratio."

Gregg Gilbert, Merrill Lynch (3/4/13) "We now see enough total return potential over the next year to justify a Buy rating for Merck & Co. Inc. . .we like its above-average dividend (4% yield) and expect some important pipeline updates this year."

Catherine Arnold, Credit Suisse (2/25/13) "Merck & Co. Inc. shares could be unleashed post the upcoming interim look at the Vytorin IMPROVE-IT trial. Street expectations are skewed to the negative and we view this as an opportunity to buy the stock as we see a favorable risk-reward on this catalyst, more positive catalysts following, low valuation and a 4% dividend yield. . .we reiterate our Outperform rating on the company (target price: $52) with its undervalued pipeline, attractive valuation and strong yield."

Alex Arfaei, BMO Capital Markets (2/15/13) "The most important upcoming event for Merck & Co. Inc. is the interim analysis of the Zetia/Vytorin IMPROVE-IT trial in March. The franchise accounts for 9% of Merck's revenues and we estimate 17% of its net income. . .although we remain cautious about the IMPROVE-IT interim analysis, we maintain our Outperform rating based on longer-term growth prospects. . .with a diverse pipeline, including a number of first-in-class drugs in high-potential markets, Merck has significant potential growth drivers. . .the company is not over dependent on any one particular pipeline drug; however, we agree that Anacetrapib (for atherosclerosis) and MK- 8931 (for Alzheimer's) could be transformative."

Catherine Arnold, Credit Suisse (2/4/13) "We see the risk/reward for Merck & Co. Inc. as attractive going into the potential interim read for the Vytorin IMPROVE-IT study in mid-March and upside from other sources in 2013 and 2014. . .the product story is improving, Odana is delayed not dead and IMPROVE-IT odds of success are better than consensus thinks (we think 60–70% chance success in March). . .the product story is getting better. . .2013 positive catalysts include PD1 (ASCO), suvorexant and Bridion launches, and BACE inhibitor readouts."

Merck & Co. Inc. Content

Corporate Presentation (4/12/13)

Animal Health Overview (11/9/12)

Back to Top

Would you like additional information on Large Cap Biotechnology/Pharmaceuticals companies?

YES

disable